Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 5
---
 trials and for commercial use, if approved;          |

| ● | the                                                                                            
 rate and degree of market acceptance of CER-1236 and any other product candidates we may       
 develop, as well as the pricing and reimbursement of CER-1236 and any other product candidates 
 we may develop, if approved;                                                                   |

| ● | our                                                                                      
 expectations regarding our ability to obtain, maintain, protect and enforce intellectual 
 property protection for CER-1236 and for any other product candidate;                    |

| ● | our                                                                                         
 ability to operate our business without infringing, misappropriating or otherwise violating 
 the intellectual property rights of third parties;                                          |

| ● | our                                                                        
 ability to realize the anticipated benefits of any strategic transactions; |

<div align='center'>iii</div>

| ● | our                                                                                        
 ability to attract and retain the continued service of our key personnel and to identify,  
 hire, and then retain additional qualified personnel and our ability to attract additional 
 collaborators with development, regulatory and commercialization expertise;                |

| ● | our                                                         
 ability to maintain proper and effective internal controls; |

| ● | the                                                                                      
 ability to obtain or maintain the listing of our Common Stock and public warrants on the 
 NASDAQ Stock Market (“Nasdaq”);                                                          |

| ● | the                                                                                         
 impact of macroeconomic conditions and geopolitical turmoil on our business and operations, 
 including interest rates, inflationary pressures, capital market disruptions, changes in    
 governmental agencies, international tariffs, trade protection measures, economic sanctions 
 and economic slowdowns or recessions;                                                       |

| ● | our                                                                                          
 expectations regarding the period during which we will qualify as an emerging growth company 
 under the Jumpstart Our Business Startups Act of 2012 and as a smaller reporting company     
 under the federal securities laws; and                                                       |

| ● | our anticipated use of our existing cash, cash equivalents and equity 
 securities.                                                           |

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described in “Risk Factors” and elsewhere in this Quarterly Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified,